The
tolterodine sustained-release prescription composition comprises a core layer, an isolating layer, a sustained-release layer and an enteric-coated layer, the core layer is a
sucrose pellet core, and the surface of the core layer is coated with
tolterodine tartrate and hydroxypropyl methylcellulose; the
isolation layer is made of hydroxypropyl methylcellulose, and the thickness of the
isolation layer is 10-20 microns; the sustained-release layer is prepared from an
ethyl cellulose aqueous dispersion and
triethyl citrate, and
silicon dioxide nanoparticles are added; and the enteric-coated layer is
acrylic resin and is dissolved when the pH value is greater than or equal to 5.5. The accumulated
dissolution rate of the composition in simulated gastric juice with a pH value of 1.2 within 2 hours is less than or equal to 10%, the accumulated
dissolution rate in simulated
intestinal juice with a pH value of 6.8 within 7 hours is more than or equal to 85%, and the accumulated
dissolution rate in a
buffer solution with a pH value of 4.5 within 3 hours is reduced by more than 20% compared with a
reference preparation; through
collaborative design of multiple
layers of coatings, collaborative reinforcement of the
plasticizer and the nanoparticles and introduction of the pH
response type enteric-coated layer, the
acid resistance, the release stability and the targeting property of the
medicine are remarkably improved, the problems of burst release of gastric juice and unstable release of intestinal tracts of a traditional preparation are solved, and the preparation has outstanding clinical application value.